Zopiclone Biogaran

Quick links

Choose a section

Quick links to important sections

Advertisements

Zopiclone Biogaran

Advertisements
Advertisements

Method of action: Hypnotic

Treatment option: Insomnia

Advertisements

Overview of Zopiclone Biogaran

Property Description
Active ingredient Zopiclone (INN)
Form Film-coated tablet
Pharmacological class Non-benzodiazepine hypnotic (Cyclopyrrolone)
Common use Addressing short-term difficulties with sleep
Origin Synthetic

What Type of Medicine is Zopiclone Biogaran?

Zopiclone Biogaran is a prescription-only hypnotic agent classified pharmacologically as a cyclopyrrolone. This medication belongs to the family of non-benzodiazepine hypnotics, widely known as Z-drugs, which are specifically designed to address difficulties related to sleep. Under the Anatomical Therapeutic Chemical (ATC) system, this substance is categorized with the code N05CF01 as a benzodiazepine-related drug. The medication is characterized by its ability to promote rest rapidly.

The drug's designation as a Z-drug distinguishes its structure from traditional benzodiazepine sedatives, although it shares the ultimate purpose of promoting rest. Zopiclone Biogaran is a brand marketed primarily in European regions, where it is established as a generic formulation of the active compound zopiclone.

Composition, Form, and Chemical Origin

The active substance in this preparation is zopiclone, a chemically synthetic compound that is presented for the oral route of administration as a film-coated tablet. Zopiclone is a single-ingredient product, containing only the INN compound as the sole therapeutically active agent.

Zopiclone is a racemic mixture (±-zopiclone) of two stereoisomers. The tablets are engineered with solid excipients to ensure standardized delivery of the zopiclone compound. This class of agents is indicated for the management of short-term insomnia based on their general hypnotic effect. The consistent form of the film-coated tablet ensures the delivery of the synthetic compound.

The Function of Zopiclone as a Sleep Aid (General Purpose)

The overall function of zopiclone is to promote rest by facilitating the brain's natural calming processes. It achieves this by selectively enhancing the effects of the inhibitory neurotransmitter Gamma-aminobutyric acid (GABA). This selective action on the GABAergic system allows the medication to support the body in overcoming the neural hyper-arousal often associated with insomnia. The general purpose of the drug is to aid individuals who experience typical symptoms of short-term sleep disturbance, such as having difficulty falling asleep or waking frequently during the night, by supporting the transition to a sustained, restful state.

Advertisements

What side effects are possible with Zopiclone Biogaran?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Zopiclone as officially documented by regulatory authorities. The adverse effects are classified by frequency and categorized by the organ systems they affect, following the established framework of the Summary of Product Characteristics (SmPC) and FDA labeling.


Official Adverse Reactions by Frequency

Common (affecting 1 to 10 users in 100): The most frequently reported effects include taste disturbance (dysgeusia), drowsiness (somnolence), dry mouth, and headache.

Uncommon to Very Rare: Less frequent effects listed in official documents include nausea, vomiting, dizziness, vertigo, fatigue, skin rash, pruritus, and eye disorders like diplopia. Rare but serious hypersensitivity reactions, such as angioedema and anaphylactic reactions, are also documented.


Serious Adverse Reactions and Safety Constraints

The prescribing information notes the potential for complex sleep behaviors, where individuals engage in activities such as sleepwalking while not fully awake, with subsequent amnesia. The risk of developing physical and psychological dependence increases with the dose and the duration of treatment, potentially leading to withdrawal phenomena upon abrupt discontinuation.

Safety is also defined by formal constraints. Zopiclone is officially contraindicated in patients with conditions such as severe respiratory failure, severe hepatic insufficiency, sleep apnoea syndrome, and Myasthenia Gravis.


Population-Specific Notes

The label indicates that dizziness and sedation may be more pronounced in older adults, increasing the risk of falls. For patients with hepatic impairment, a reduced dosage is specified due to the medicine’s slower clearance, a safety measure documented in regulatory texts.

Advertisements

Overdose and Emergency Response

Overdose of Zopiclone generally results in excessive Central Nervous System (CNS) depression. Officially documented clinical manifestations include somnolence (drowsiness), lethargy, confusion, ataxia (loss of coordination), and muscular weakness known as hypotonia. The effects can progress to more severe systemic compromise, involving the respiratory and cardiovascular systems.

These severe outcomes may include respiratory depression (shallow breathing), profound hypotension (low blood pressure), and coma. A potentially fatal outcome has been reported, particularly when the medicine is co-ingested with other CNS-depressant agents, such as alcohol or opioids, which significantly increases the risk of severe sedation and respiratory failure.

Individuals must seek immediate medical attention by contacting a doctor or going to a hospital emergency department straight away in cases of suspected overdose. Management is based on general symptomatic and supportive measures. This includes maintaining a clear airway and providing close medical monitoring of vital and cardiac signs.

Procedural instructions noted in regulatory documents may include the consideration of gastric lavage or administration of activated charcoal shortly after ingestion. The antagonist flumazenil may be considered in severe cases, but supportive care remains the cornerstone of management. Elderly patients are noted in regulatory labeling to be at an increased risk of severe effects.

Advertisements

Therapeutic Uses of Zopiclone Biogaran

What Zopiclone Biogaran Treats: Main Uses and Benefits

Zopiclone Biogaran is commonly used for short-term symptomatic assistance in managing sleep difficulties in adults. This is a therapeutic area relevant within clinical settings that involve acute or unstable symptom patterns. The use is applied across domains where additional symptomatic support is needed due to heightened patient distress from sleeplessness.

It is relevant for easing symptoms that cluster as sleep initiation failure (difficulty falling asleep) and sleep maintenance disruption (frequent nocturnal awakenings). The medication may be part of symptomatic management applied in situations requiring short-term symptomatic support when the resulting sleep deficit creates noticeable functional strain or discomfort.

“This short-term symptomatic support assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.”

Managing Symptom Clusters

A key benefit is helping the patient achieve rest more readily and supporting a more continuous state of rest, which assists with maintaining a sense of stability when symptoms are more noticeable. Its application is relevant when short-term symptomatic assistance is needed, supporting the patient during difficult episodes by easing distress.


Quick Fact: Support for Acute Sleep Deficit

Zopiclone is primarily used for conditions characterized by periods of heightened symptoms that lead to significant functional strain, offering supportive relief when symptoms become momentarily overwhelming.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Regulatory documents define specific populations and conditions that determine eligibility for Zopiclone Biogaran use. The medicine is contraindicated (absolutely must not be used) for several groups:

Contraindicated Populations
Patients with Myasthenia Gravis
Patients with Severe Hepatic Insufficiency or Severe Impairment of Respiratory Function (e.g., severe sleep apnoea syndrome)
Individuals with known hypersensitivity to zopiclone or excipients
Patients who have previously experienced complex sleep behaviours (like sleep-driving) after taking zopiclone
Children and adolescents under 18 years of age (safety and effectiveness are not established)

Use is not recommended during pregnancy and breastfeeding due to potential risks to the infant. Use is also restricted for specific patient categories:

Eligibility-Related Restrictions
Older adults (ge 65 years)
Patients with non-severe hepatic or renal impairment
Patients with chronic respiratory insufficiency

These groups are eligible but require the prescription to begin at a lower initial dose (typically 3.75 mg), as documented in regulatory guidelines, to minimize risk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zopiclone’s interaction profile is primarily defined by its effects on the Central Nervous System (CNS) and its metabolism by liver enzymes.

Pharmacodynamic Interactions (Enhanced CNS Depression)

Combining Zopiclone with alcohol is strongly advised against, as this combination significantly enhances the central depressant effect, increasing the risk of profound sedation, respiratory depression, coma, and complex sleep behaviors like sleep-driving.

Concomitant use with other CNS depressants also produces additive effects. These agents include antipsychotics, other hypnotics, anxiolytics/sedatives, certain antidepressants, anti-epileptic drugs, narcotic analgesics (opioids), and sedative antihistamines. Use of Zopiclone with opioids must be limited to the lowest effective dose for the shortest duration due to the risk of severe sedation and respiratory depression.

Pharmacokinetic Interactions (Enzyme Effects)

Zopiclone is metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme in the liver. Drugs that affect this enzyme can alter the concentration of Zopiclone in the body:

  • CYP3A4 Inhibitors: Medicines such as erythromycin, clarithromycin, ketoconazole, itraconazole, and ritonavir can decrease Zopiclone metabolism, leading to higher plasma concentrations and an enhanced hypnotic effect, potentially requiring a dose reduction of Zopiclone.
  • CYP3A4 Inducers: Medicines like rifampicin, carbamazepine, phenobarbital, phenytoin, and St. John's wort can increase Zopiclone metabolism, lowering its plasma concentration and potentially reducing its effectiveness.

Caution should be exercised to ensure at least seven to eight hours of uninterrupted sleep after taking Zopiclone to mitigate the risk of next-day impairment, which is amplified when interactions are present.

Advertisements

Mechanism of Action

️ How Zopiclone Biogaran Works

Zopiclone exerts its primary effect as a Positive Allosteric Modulator (PAM) of the Gamma-aminobutyric acid ( GABA-A) receptor complex, which is the central inhibitory target within the brain. The drug binds to a specific site on the receptor and enhances the action of the endogenous neurotransmitter GABA, leading to decreased neuronal firing rates.

This molecular interaction initiates a cascade that significantly increases the flow of chloride ions ( Cl^-) through the neuronal membrane. This Cl^- influx causes neuronal hyperpolarization and reduced cellular excitability.

This systemic reduction in Central Nervous System ( CNS) excitability contributes to CNS depression. Zopiclone exhibits preferential affinity for GABA-A receptor subtypes containing the alpha1 subunit. This specific modulatory mechanism is subject to homeostatic constraints; continuous engagement can lead to a decrease in receptor responsiveness, resulting in pharmacodynamic tolerance over time.

Advertisements

Dosage and Administration Information

How to Use Zopiclone Biogaran

This section describes the administration and dosing guidelines for Zopiclone Biogaran. Zopiclone is approved for oral administration as a film-coated tablet.


Official Dosing and Schedule

Instruction Guideline
Route of Administration Oral use only.
Standard Adult Dose A single dose of 7.5 mg. The maximum daily dose must not exceed 7.5 mg.
Timing and Frequency Taken once daily, immediately or shortly before retiring. No re-administration is permitted during the same night.
Administration The tablet should be swallowed whole. It may be taken with or without food.

Duration and Adjustments

Guidelines specify that zopiclone should be used for the shortest duration possible, with the total course, including any necessary dose tapering, not exceeding four weeks.

To ensure proper use, dose adjustments are required for certain populations:

  • Older Adults (Geriatric): Treatment typically begins with a reduced dose of 3.75 mg. This lower starting dose is also recommended for patients with hepatic insufficiency (liver problems), renal impairment (kidney problems), or chronic respiratory insufficiency.
  • Pediatric Patients: Zopiclone is not recommended for use in children and adolescents under 18 years of age.

Taking the tablet requires the patient to be able to commit to a full night's sleep of approximately 7 to 8 hours immediately following administration.

Advertisements

Recent Clinical Evidence

Zopiclone Biogaran has been studied for its use in managing difficulties with sleep, which includes both problems falling asleep (sleep initiation) and waking up frequently during the night (sleep maintenance). The research base primarily consists of short-term, randomized controlled trials (RCTs). These RCTs were used in studies examining patient-reported experiences of sleep, as well as objective measures. Researchers primarily examined outcomes related to the time taken to fall asleep (sleep latency) and the overall total sleep time. These studies typically ran for defined time intervals, ranging from a single night up to four to six weeks of continuous use.

Comparative research has also examined how Zopiclone Biogaran compared to a placebo and to other sedative medications. These trials explored whether one compound was associated with different measurements of sleep outcomes compared to another. In these head-to-head comparisons, research describes measurements of key sleep outcomes that were observed across the groups. This comparative evidence is relevant in trials assessing short-term or episodic symptom patterns.

The research base is focused on short-term use, which means the follow-up durations were limited in most high-quality controlled studies. The controlled research provides limited information for long-term outcomes or the consequences of using the medication continuously for many months. Long-term effects are not fully established.

Specific research was evaluated in certain populations, particularly older adults (aged 60 and above). Studies monitored whether measurements of sleep metrics appeared to differ in this group compared to younger adults. However, data for certain groups remain insufficient, and results apply only to the populations studied. One area of uncertainty relates to the absolute magnitude of the findings; while differences compared to placebo are statistically measured, the magnitude of the change in sleep outcomes is often described in scientific literature as small. Furthermore, evidence quality varies across studies, and methodological inconsistency exists.

Key Studies & References

  1. Meta-analysis of benzodiazepine use in the treatment of insomnia - CMAJ (Includes zopiclone in alternative drug therapies for comparison)
  2. Association Between Z Drugs Use and Risk of Cognitive Impairment in Middle-Aged and Older Patients With Chronic Insomnia (Study on long-term cognitive outcomes in older adults)
  3. Eszopiclone for treating insomnia - Health Technology Briefing March 2024 (NIHR briefing referencing key short-term and long-term trials)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Zopiclone Biogaran (FAQ)


Q: What is the typical time it takes for Zopiclone Biogaran to start working?

Official prescribing information indicates that Zopiclone is designed to act quickly. Its effects typically begin within 1 hour of administration. Administration guidelines recommend taking the drug immediately before going to bed.

Q: How long do the effects of Zopiclone Biogaran usually last?

Official pharmacokinetic data describes the elimination half-life of Zopiclone as approximately 5 hours in most healthy adults. This measure relates to the time it takes for half of the drug to be cleared from the body, which is consistent with the required commitment to a full night's sleep after taking it.

Q: What information is provided about Zopiclone Biogaran if a dose is accidentally forgotten?

According to official consumer medicine information, if a dose is forgotten, the drug is only taken if the user can still commit to a full 7 to 8 hours of uninterrupted sleep. If this is not possible, the missed dose is otherwise skipped entirely to help prevent lingering residual effects the next day.

Q: Does Zopiclone Biogaran cause vivid or strange dreams?

Official regulatory documents list nightmares as a possible side effect, though it is typically described as an uncommon or rare psychiatric disorder. This information comes from adverse event reports collected during clinical use and ongoing safety monitoring.

Q: Can Zopiclone Biogaran cause anxiety or mood changes according to regulatory documents?

The official Summary of Product Characteristics (SmPC) notes that certain psychiatric disturbances such as restlessness, agitation, or depressed mood have been reported. Furthermore, anxiety is specifically mentioned as a potential symptom that may occur during the withdrawal period.

Q: What is the known risk of overdose with Zopiclone Biogaran?

Regulatory information states that symptoms of an overdose are typically an exaggeration of the drug’s hypnotic effects. This may include severe drowsiness, confusion, deep sleep, shallow breathing, and the potential risk of coma.

Q: Does Zopiclone Biogaran interact with common over-the-counter pain relief medications?

Official interaction warnings focus heavily on combining Zopiclone with strong narcotic painkillers (opioids), which carries a risk of increased sedation and respiratory issues. The regulatory documents do not list a specific warning for common over-the-counter non-narcotic pain relievers like paracetamol or ibuprofen.

Q: Is Zopiclone Biogaran safe to use with Grapefruit juice, as noted for other drugs?

Official interaction data indicates that substances which inhibit the CYP3A4 enzyme in the liver, such as grapefruit juice, may increase the concentration of Zopiclone in the blood. This enhanced level could potentially increase the hypnotic effects.

Q: Is Zopiclone Biogaran the exact same as Zimovane or other Zopiclone brands?

As a generic formulation, Zopiclone Biogaran contains the identical active ingredient (Zopiclone) found in other brands like Imovane or Zimovane. However, all generic products may use different non-active excipients (filler materials) compared to the originator brand.

Q: How is Zopiclone Biogaran chemically different from Zoldipem or similar non-benzodiazepine hypnotics?

Zopiclone is classified chemically as a cyclopyrrolone drug, which is its distinct molecular family. For comparison, Zoldipem (zolpidem) belongs to the imidazopyridine family. While both are Z-drugs, their structures are chemically distinct.

Q: Does official research mention Zopiclone Biogaran use in patients with chronic sleep disorders?

Official regulatory documents clearly state that Zopiclone is intended for short-term treatment only. For this reason, use conditions limit it to the shortest possible duration. The safety and effectiveness for continuous long-term use—meaning beyond four weeks—have not been established in controlled clinical research.

Q: What does the term 'rebound insomnia' mean in the context of stopping Zopiclone Biogaran?

Rebound insomnia is defined in official warnings as a transient (temporary) syndrome. It describes when the original sleep problems being treated recur in an enhanced or worsened form when the medication is abruptly stopped. The regulatory warnings related to this phenomenon often emphasize the importance of gradual cessation.

Advertisements

How should Zopiclone Biogaran be stored and disposed of?

How to Store and Dispose of Zopiclone Biogaran

Storage Requirements

Zopiclone film-coated tablets must be stored securely, strictly out of the sight and reach of children, as required by regulatory authorities. To maintain product stability, the medicine must be stored at a temperature that is typically specified as below 25 C or 30 C, depending on the regional label. The product must not be used after the expiry date (EXP) indicated on the outer packaging.

️ Disposal Instructions

Official regulatory guidance prohibits discarding Zopiclone via wastewater or household waste. Instead, unused or expired medication and associated waste material must be disposed of in accordance with local requirements. Patients are instructed to ask a pharmacist for the proper method of disposal to ensure adherence to environmental protection standards.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zopiclone Biogaran found in:

A-Z Index: